Header Logo

Connection

HELEN HESLOP to B-Lymphocytes

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about B-Lymphocytes.
HELEN HESLOP
Connection Strength
0.543
B-Lymphocytes
  1. Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol. 2015 Jul; 35(5):445-8.
    View in: PubMed
    Score: 0.091
  2. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.082
  3. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26.
    View in: PubMed
    Score: 0.078
  4. How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8.
    View in: PubMed
    Score: 0.062
  5. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
    View in: PubMed
    Score: 0.036
  6. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101.
    View in: PubMed
    Score: 0.030
  7. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93.
    View in: PubMed
    Score: 0.027
  8. Measuring gene-transfer efficiency. Nat Med. 1996 Dec; 2(12):1280-1.
    View in: PubMed
    Score: 0.025
  9. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.023
  10. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
    View in: PubMed
    Score: 0.022
  11. Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br J Haematol. 1991 Oct; 79 Suppl 1:14-6.
    View in: PubMed
    Score: 0.018
  12. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.017
  13. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol (1978). 1988; 30(5-6):317-9.
    View in: PubMed
    Score: 0.014
  14. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
    View in: PubMed
    Score: 0.009
  15. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol. 1990 Jan 15; 144(2):541-7.
    View in: PubMed
    Score: 0.004
  16. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.